 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|---|
|
   |
| RedChip Issues New Report on PSID It is a Must Read with a Price Target of .54! |
|
 Hot Stock to Watch |
Company: PositiveID Corporation (OTCQB: PSID)
|
Last:
Price: 0.131
Change (%): + 0.0011 (0.85)
Volume: 338,349 |
 |
RESEARCH REPORT
July 18, 2016
 |
 |
|---|
Company Overview
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems and mobile technology vehicles, with a focus on point-of-need bio-threat detection, rapid medical testing, and homeland security. The Company’s products lower the cost, reduce the time needed to administer the test/perform the service, and/or provide more sensitive/specific test results relative to current competing solutions.
Valuation
We are valuing PSID using 1.5x EV/Sales multiple applied to our FY2019 sales estimate of 27.6 million dollars. This derives a target price of $0.54.
Company Highlights
- PSID is developing the Firefly Dx, a hand-held point of need molecular diagnostic system that delivers results in under 30 minutes. This cartridge based system, when completed, will be faster, fully automated and far less costly than existing lab based testing
- The Infectious disease diagnostic market is expected to grow at CAGR 7.9% to reach 18.16 billion dollars by 2019
- Acquisitions have led to projected 2016 revenue guidance of $5-$6 million, representing a potential YoY revenue increase of 100%
- Increased threats of Bioterrorism sparked the Department of Homeland Security (DHS) to deploy the Bio-watch program for automated bio-threat detection; M-BAND has the potential to generate significant revenue and net income for PSID
- The Firefly Dx System is highly attractive from an economic perspective at an estimated price of $5,000 per unit, and at volumes, $1,000 per unit
- Pursuing a government contract or commercial partner to help fund final development of smaller, field-able Firefly Dx prototype for testing by third parties to prepare for commercialization
- Mobile Lab business completed 80 projects in the first half of 2016
- Recently acquired the Caregiver non-contact, infrared thermometer, marketed by Thermomedics; the global thermometer market is projected to reach 1 billion dollars by 2020, with infrared thermometers experiencing the fastest growth driven in part by concerns over the spread of highly infectious diseases
- Recent global Epidemic outbreaks like Ebola and Zika remain a major public health concern in the United States and around the world
PSID is developing the Firefly Dx, a hand-held point of need molecular diagnostic system that delivers results in under 30 minutes. This cartridge based system, when completed, will be faster, fully automated and far less costly than existing lab based testing. Using advanced molecular diagnostic technologies and real-time polymerase chain reaction (PCR) chemistry it will deliver lab quality results faster and more cost-effective than competing solutions.
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
